Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease

NAActive, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

March 31, 2028

Conditions
Tricuspid RegurgitationTricuspid Valve DiseaseCarcinoid SyndromeCarcinoid Heart Disease
Interventions
DEVICE

Transcatheter Tricuspid Valved Stent Graft

All participants meeting the inclusion and none of the exclusion criteria will be enrolled. A custom-made Transcatheter Tricuspid Valved Stent Graft based on CT to define anatomic dimensions will be made. The system consists of a custom-made valved stent graft delivery system, a custom-made valved stent graft bioprosthesis and a loading system. The bioprosthesis is self-expanding and consists of a stent graft spanning from the inferior vena cava to the superior vena cava and a lateral bicuspid valve element made of thin porcine pericardial leaflets requiring a low closing pressure, and Nitinol support structures. The participants will undergo a minimally invasive, catheter-based procedure to implant the bioprosthesis which is delivered through a 24 French delivery system via transfemoral access. The device can be repositioned and is retrievable.

Trial Locations (1)

E1 1BB

Barts Health NHS Trust, London

All Listed Sponsors
collaborator

Royal Free Hospital NHS Foundation Trust

OTHER

lead

Queen Mary University of London

OTHER